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Abstract: Immunotherapy has recently changed the treatment of several cancers. We performed
a literature-based meta-analysis of randomised controlled trials to assess the efficacy of the novel
immune checkpoint inhibitors (ICIs) in metastatic gastric cancer. The main outcome was overall
survival. Based on age (cut-off agreed at 65 years), tumour location (gastric vs. gastro-oesophageal
junction), programmed death-ligand 1 (PD-L1) status, sex and Eastern Cooperative Oncology Group
(ECOG) status (1 vs. 0), we scheduled a subgroup analysis for the overall survival. Three studies
were included in the analysis for a total of 1456 cases (811 cases were in the experimental group
and 645 cases in the control group). The pooled analysis showed improved overall survival in
the experimental arm in the absence of statistical significance (hazard ratio (HR) = 0.87, 95% CI:
0.64–1.18; p = 0.37). The subgroup of patients with PD-L1-positive tumours (HR = 0.82 vs. 1.04) and
gastro-oesophageal junction cancer (HR = 0.82 vs. 1.04) showed a statistically significant advantage of
overall survival. This study supports the efficacy of immune checkpoint inhibitors in the subgroup of
patients with metastatic gastric cancer with PD-L1-positive and gastro-oesophageal junction tumour
location. Future studies are needed with the aim of identifying reliable predictive biomarkers of
ICI efficacy.
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1. Introduction
Gastric cancer (GC) accounted for over 1,000,000 new cases in 2018 with an estimated 783,000 deaths,
making it the fifth most common cancer worldwide and the third leading cause of cancer deaths [1].
Metastatic GC is managed with a combination of chemotherapy composed of platinum compounds plus
fluoropyrimidines [2,3]. For patients with progression of disease on first-line chemotherapy, treatment
options include chemotherapy with irinotecan, taxanes (paclitaxel or docetaxel) and ramucirumab
(a monoclonal antibody against vascular endothelial growth factor 2 (VEGFR2) used in monotherapy or
in combination with paclitaxel) [4,5]. Although no standard treatment is recommended by guidelines
for patients who failed two or more lines of therapy, two drugs, apatinib (a tyrosine kinase inhibitor that
selectively inhibits VEGFR2) and trifluridine/tipiracil (TAS-102), were shown to increase survival when
compared to a placebo as third-line or later therapy for advanced GC [6,7]. Nonetheless, the prognosis
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of these patients remains very poor, underlying the need to develop new treatment options with
acceptable safety profiles.
Immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the treatment of
several solid and haematological cancers. ICIs work by inhibiting programmed death-1 (PD-1) receptor
or ligand (PD-L1) [8]. There is a strong rationale for the use of ICIs for advanced GC; in fact, up
to 65% of gastric cancers overexpress PD-L1 [9–11]. Based on the results of a phase II study [12],
pembrolizumab (an anti-PD-1 ICI) has been approved by the food and drug administration (FDA) for
the treatment of patients with recurrent locally advanced or metastatic GC whose tumours express
PD-L1. However, in the following phase III trial, no remarkable overall survival (OS) outcomes
have been reported with pembrolizumab when compared with paclitaxel as a second-line regimen
in PD-L1-positive advanced gastric cancer or gastro-oesophageal junction cancer [13]. Additional
phase III studies on ICIs for metastatic GC showed discordant results [14,15] and nivolumab has been
approved in Japan [16]. In this paper, we performed a meta-analysis to evaluate the impact of ICIs on
the outcomes of patients with metastatic GC focusing on the possible predictor of efficacy.
2. Results
2.1. Literature Review and Characteristics of the Included Studies
The search yielded 770 potentially relevant articles. A total of 506 studies were excluded as
duplicates. After viewing the titles and abstracts of the 264 remaining studies, the full texts of 13 studies
were retrieved, and three studies [13–15] were included in the analysis (Figure 1). Table 1 summarized
the characteristics of the evaluated studies. A total of 1456 cases were included: the experimental arm
included 811 cases whereas the control arm included 645 cases. Two studies [13,14] investigated a PD-1
ICI as an experimental drug, while the placebo was the control arm of one study [14]. All studies were
phase III randomised controlled trials (RCTs). The mean Jadad score was 4.3 (Table 1). No publication
bias was estimated on account of the small number of included trials.
Table 1. Characteristics of the analysed trials.
Study PrimaryEndpoint
Number of
Patients
Experimental
Arm
Number of
Patients
Control
Arm
Experimental
Drug/Control
Arm
Geographic
Region
Line of
Therapy
Programmed
Death-Ligand
1 (PD-L1)
Positivity
Jadad
Score
ATTRACTION-2 OS 330 163 Nivolumab/Placebo Asian III/IV/V
staining in 1%
or more of
tumour cells
5
JAVELIN
Gastric 300 OS 185 186
Avelumab/
Chemotherapy
European/North
America/Asian III
by using an
immunohisto
chemistry-based
companion
diagnostic
(PD-L1
pharmDx) test
4
KEYNOTE-061 OS/PFS 296 296 Pembrolizumab/Chemotherapy
European/North
America/Asian II
PD-L1
combined
positive score
CPS of 1 or
higher
4
OS: overall survival, PFS: progression free survival.
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Tables 2 and 3 summarize characteristics of patients and efficacy data of the evaluated studies. 
The pooled analysis showed improved OS in the experimental arm, in the absence of statistical 
significance (hazard ratio (HR) = 0.87, 95% CI: 0.64–1.18; p = 0.37, Figure S1). A random-effects model 
was used to perform the analysis (I2 = 87%). Furthermore, the pooled analysis showed no 
improvement in progression free survival (PFS) with the use of ICIs, in comparison to no ICIs (HR = 
1.16, 95% CI: 0.62–2.17; p = 0.65, Figure S2). A random-effects model was used to perform the analysis 
(I2 = 97%). Lastly, each study was investigated for the response rate: 67 out of 749 (8.9%) patients for 
the experimental arm and 45 out of 613 (7.3%) patients for the control arm showed a tumour response. 
Using the Mantel–Haenszel method, the pooled response rate was 1.38 (95% CI 0.30–6.46; p = 0.68; I2 
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2.2. Efficacy Data
Tables 2 and 3 summarize characteristics of patients and efficacy data of the evaluated studies.
The pooled analysis showed improved OS in the experimental arm, in the absence of statistical
significance (hazard ratio (HR) = 0.87, 95% CI: 0.64–1.18; p = 0.37, Figure S1). A random-effects
model was used to perform the analysis (I2 = 87%). Furthermore, the pooled analysis showed no
improvement in progression free survival (PFS) with the use of ICIs, in comparison to no ICIs (HR = 1.16,
95% CI: 0.62–2.17; p = 0.65, Figure S2). A random-effects model was used to perform the analysis
(I2 = 97%). Lastly, each study was investigated for the response rate: 67 out of 749 (8.9%) patients for
the experimental arm and 45 out of 613 (7.3%) patients for the control arm showed a tumour response.
Using the Mantel–Haenszel method, the pooled response rate was 1.38 (95% CI 0.30–6.46; p = 0.68;
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I2 = 79%; Figure 2). The analysis was performed using a random-effects model and did not reach any
statistical significance. Data on disease control rate could be obtained only from two studies [14,15],
and showed disease control in a total of 142/453 (31.3%) patients in the experimental arm, and in a
total of 103/317 (32.4%) patients in the control group. For disease control rate, a meta-analysis was
not performed.
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Table 2. Data on overall survival, progression-free survival and tumour response of the included studies.
Study
OS (Months) PFS (Months) Overall ResponseRate (%)
Disease Control
Rate (%)
Treatment
Duration of
Experimental
Drug (Months)
Exp
Arm C Arm
Exp
Arm C Arm
Exp
Arm C Arm
Exp
Arm C Arm Exp Arm
ATTRACTION-2
2017 5.26 4.14 1.61 1.45 11.2 0 40.3 25 1.92
JAVELIN Gastric
300 4.6 5.5 1.4 2.7 2.2 4.3 22.2 44.1 8.0 *
KEYNOTE-061 6.7 8.3 1.5 4.1 11.1 12.5 NR NR 4.4
Exp: experimental; C: control; NR: not reported *: weeks.
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Table 3. Characteristics of patients in the evaluated studies.
Study
Median
Age/Male
Patients %
ECOG > 0% DiffuseHistolog %
Primary Lesion
GEJ Junction %
Prior
Surgery %
Number of
MetastaticSites > 2 %
Peritoneal
Metastasis %
>II Previous Line
of Treatment % Previous Ram. %
E C E C E C E C E C E C E C E C E C
ATTRACTION-2 62/69 61/73 71 71 NR NR NR NR 60 ◦ 64 ◦ 75 ◦◦ 73 ◦◦ 19 26 79 72 11 13
JAVELIN
Gastric 300 59/76 61/68 64 67 NR NR 34 26 NR NR NR NR NR NR 0 0 NR NR
KEYNOTE-061 62/68 60/70 57 53 29 22 30 32 36 38 NR NR 28 28 0 0 NR NR
E: experimental arm; C: CONTROL arm; ECOG: Eastern Cooperative Oncology Group; NR: not reported; GEJ: gastro-oesophageal; Ram: ramucirumab; ◦ Gastrectomy; ◦◦ ≥ 2 organs
with metastases.
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According to the trial protocol, a subgroup analysis was performed to investigate the influence of
PD-L1 status, age, tumour location, sex and Eastern Cooperative Oncology Group (ECOG) performance
status on OS (Table 4). The analysis of OS according to PD-L1 tumour expression status showed that
ICIs significantly improved OS in patients with PD-L1-positive tumours (HR = 0.82 95% CI: 0.67–0.99;
p = 0.04) in comparison to PD-L1-negative patients (HR = 1.04 95% CI: 0.77–1.42; p = 0.80) Figure 2.
In addition, when we stratified patients according to the tumour location, we found that OS was
significantly higher in the experimental arm versus the control arm in patients with gastro-oesophageal
junction tumours (HR = 0.67 95% CI: 0.48–0.92; p = 0.01) compared to gastric tumours (HR = 0.92
95% CI: 0.66–1.29; p = 0.63) Figure 3. Lastly, there were no other differences when applying other
stratification factors (Table 4).
In regard to the toxicity, a total of 386/808 (47.8%) patients for the ICIs and a total of 406/614 (66.1%)
patients in the control arm reported all-grade treatment-related adverse events (Figure S3). Using
the Mantel–Haenszel method for combining trials, the pooled risk ratio was 0.86 (95% CI 0.54–1.36;
p = 0.51; I2 = 95%; Figure S3). The analysis was performed using a random-effects model. In addition,
a total of 94/808 (11.6%) patients for the ICIs and a total of 172/614 (28%) patients in the control arm
reported all-grade treatment-related adverse events (Figure S4). A pooled analysis showed a risk ratio
of 0.59 (95% CI 0.22–1.55; p = 0.28; I2 = 91%; random-effects model Figure S4). These data showed a
non-statistically significant trend in favour of a lesser toxicity for ICIs.
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Table 4. Subgroup analysis of immune checkpoi t inhibitors (ICIs) compared to the control arm in
gastric cancer.
HR 95% CI p Value I2 % p Value Model
PD-L1 positive
PD-L1 negative
0.82
1.04
0.67–0.99
0.77–1.42
0.04 *
0.80
0
63
0.50
0.07 Random
Age ≥ 65 years
Age < 65 years
0.76
0.89
0.52–1.11
0.66–1.19
0.16
0.41
70
67
0.04
0.05 Random
Male
Female
0.79
1,01
0.58–1.08
0.67–1.51
0.14
0.98
76
63
0.02
0.07 Random
ECOG:0
ECOG:1
0.84
0.87
0.50–1.41
0.67–1.13
0.51
0.29
82
63
0.004
0.07 Random
Gastric
Gastro-oesophageal Junction
0.92
0.67
0.66–1.29
0.48–0.92
0.63
0.01 *
80
23
0.006
0.27 Random
HR: hazard ratio; * Statistically significative
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3. Discussion
The treatment of several tumours has been revolutionized by the introduction of ICIs [17], and for
this reason, they have been evaluated in metastatic GC. Unfortunately, the here-presented meta-analysis,
including three RCTs with a total of 1456 pre-treated metastatic GC patients, and targeted with ICIs,
suggests that there is no statistically significant improvement in OS, and no advantage in terms of
PFS and tumour response rate. However, since this meta-analysis analysed only three RCTs, it is not
possible to conclude that ICIs do not work in pre-treated metastatic GC. In addition, it should be
considered that endpoints, such as PFS and response rate (RR), are not optimal in patients treated with
ICIs [18].
A high heterogeneity (I2 = 87%) was reported between the studies, which could be explained by
differences in the patient population (Tables 1 and 3). In fact, it is well-known that patient ethnicity
affects prognosis in GC patients [19]. The ATTRACTION-2 trial enrolled only Asian patients (mainly
from Japan), while the JAVELIN Gastric 300 and KEYNOTE-61 trials enrolled patients coming from
Europe, and in a smaller percentage from Asian countries. In addition, not all studies stratified patients
according to PD-L1 expression. Lastly, there were differences in the definition of the control arm, for
which a placebo was used in one study and chemotherapy in the other two.
Nonetheless, the negative results in terms of OS observed in our meta-analysis highlight the
pressing need for stringent patient recruitment and the identification of those who might benefit
most from ICI treatment. Recently, the Cancer Genome Atlas categorised GCs into four molecular
subtypes: Microsatellite instability (MSI)-high, Epstein–Barr virus-positive, genomically stable, and
chromosomally unstable [9]. If we use this molecular classification, MSI-high and Epstein–Barr
virus-positive are the tumour subtypes more likely to respond to ICIs: MSI-high, in view of the increased
number of somatic mutations due to DNA mismatch repair defects, and Epstein–Barr virus-positive
for the alterations related to the presence of oncogenic viruses [20]. Interestingly, two subgroups of
patients showed a statistically significant OS advantage with ICIs: PD-L1 tumour-positive patients
when compared to PD-L1 tumour-negative patients (HR: 0.82 vs. 1.04 respectively, Figure 2), and
patients with gastro-oesophageal junction tumours when compared to gastric tumours (HR: 0.67 vs. 0.92
respectively, Figure 3). The low heterogeneity (0% for the PD-L1-positive subgroup and 23% for
gastro-oesophageal junction location) further supports this data.
PD-L1 overexpression is generally associated with worse survival in patients with solid
tumours [21]. However, despite the efficacy of immunotherapy in several solid and non-solid
cancers, it is not well defined whether PD-L1 expression correlates also with the clinical response and
outcomes in patients treated with ICIs. In 2016, a meta-analysis of 20 trials involving patients with
melanoma, non-small cell lung cancer and renal cell carcinoma receiving anti-PD-1/PD-L1 antibodies
showed that PD-L1 expression is significantly associated with risk of death and clinical response
to anti-PD-1/PD-L1 ICIs in melanoma patients. Also, PD-L1 expression is associated with clinical
response in patients with non-squamous non-small cell lung cancer [22]. PD-L1 positivity is observed
in up to 65% of GC specimens [20], and even though it is widely associated with negative features,
such as tumour size, lymph node metastasis and depth of invasion, there is no consensus on the role
of PD-L1 expression as a prognostic biomarker in GC [23]. While the KEYNOTE-061 trial confirmed
a better outcome with pembrolizumab in patients with PD-L1-positive tumours [13] data from the
JAVELIN Gastric 300 and ATTRACTION-2 trials did not support the concept of PD-L1 positivity
as a predictive response marker to ICIs [14,15]. In addition, PD-L1 expression was prospectively
assessed in the KEYNOTE-061 and JAVELIN Gastric 300 trials, but was retrospectively evaluated
in the ATTRACTION-2 trial. In this context, our meta-analysis seems to confirm a survival benefit
for patients with PD-L1-positive GCs (Figure 2). However, it should be noted that the difference in
methods (distinct immunohistochemistry antibody clones, staining methods and scoring systems) and
the difference in PDL1 expression scoring systems (Table 1) do not allow for the drawing of definitive
conclusions on the role of PD-L1 expression as a biomarker for the identification of patients who are
likely to benefit from ICIs.
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PD-L1 expression was measured in tumour cells in the ATTRACTION-2 and JAVELIN Gastric
300 trials, while PD-L1 expression was measured in tumour cells, lymphocytes and macrophages in
the KEYNOTE-061 trial. Therefore, intra-tumour heterogeneity may influence the results of PD-L1
expression [24]. However, supplementary data from the JAVELIN Gastric 300 trial reported comparable
results when PD-L1 expression was measured in both tumour and immune cells [15] (data not shown).
For this reason, more prospective studies are needed.
We also found a statistically significant advantage for OS in patients with gastro-oesophageal
junction tumours when compared to gastric tumours (HR: 0.67 vs. 0.92 respectively; Figure 3). Although
the site of the primary GC in the upper third of the stomach, particularly at the gastro-oesophageal
junction or cardia, is generally considered to be a prognostic factor [25], few data are available
on the role of ICIs in unselected patients with gastro-oesophageal junction cancers. Interestingly,
a very low percentage of gastro-oesophageal junction cancer patients account for the MSI-high and
Epstein–Barr virus-positive molecular subtypes [9], implying that other clinical/molecular features
may be responsible for the higher sensitivity to ICIs, which appears to characterise gastro-oesophageal
junction tumours. Finally, some concerns may derive from the fact that we analysed two trials with
an anti-PD-1 ICI and one trial with an anti-PD-L1 ICI, and it should be supposed that one is better
than the other. In this context, a recent meta-analysis in pre-treated non-small-cell lung cancer patients
indicated a slight benefit from anti-PD-1 than from anti-PD-L1 inhibitors [26]; however, in the absence
of a direct comparison between anti-PD-1 and anti-PD-L1, no definitive conclusions are available, and
we should consider all groups of ICIs to be of equal efficacy.
There are limitations to our study: (1) the analysis was based on the literature rather than on
individual patient data; (2) a small number of studies were available; (3) heterogeneous disease
characteristics, therapy regimens and heterogeneity of disease features might have an impact on
outcome estimates; (4) an adverse events analysis was not done; (5) discrepancies within control arms
among the studies (placebo or chemotherapy) have been reported; and (6) the absence of data on
metastatic esophageal cancer.
To date, even with the availability of novel therapies [27], the prognosis of metastatic GC
remains very poor. Immunotherapy has impressively modified the treatment strategy of several
cancers and shown some efficacy in metastatic GC, especially in patients with PD-L1-positivity and
gastro-oesophageal junction tumour location. We strongly suggest that subsequent clinical trials focus
on the identification of predictive response biomarkers for a better selection of the optimal candidates
for ICIs therapies.
4. Methodology
4.1. Data Retrieval Strategies
We analysed RCTs according to the Preferred Reporting Items for Systematic Reviews Guidelines
and Meta-Analyses (PRISMA). The Web of Sciences (WOS), PubMed and Embase databases were
analysed for suitable publications with the search strategy here reported (Supplementary file 1).
The search criteria were limited to phase III RCTs and studies published before December 2018
were considered.
4.2. Inclusion Criteria
Selected trials were independently examined by two authors (P.R., A.D.G.), according to the specific
selection and exclusion criteria. Contentious points were resolved by referring to the corresponding
authors. The main inclusion criteria were: (1) patients with advanced/metastatic GC that progressed
after one line of therapy for metastatic disease; (2) a novel immune checkpoint inhibitor as the
experimental arm; (3) a placebo or chemotherapy as a control arm for comparison; (4) OS as primary
outcome and PFS as secondary outcome both showed as HR and RR (partial plus complete response)
and disease control rate (DCR) (partial plus complete response plus stable disease) both showed as
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the number of patients out of the total who reported a documented tumour response. The following
exclusion criteria were used: (1) non-randomised clinical trials; 2) <50 patients for an arm; (3) insufficient
data available to estimate the outcomes; (4) studies in the first line of treatment for metastatic GC;
and (5) studies that involved ICIs in both the experimental and control arms.
4.3. Data Collection and Quality Assessment
Hazard ratios for OS and PFS, the number of patients who reported a disease response or
disease control and characteristics of analysed studies were independently extracted by two authors.
The ICI was considered the experimental arm. The Jadad 5-item scale was used for study quality [28].
The protocol of the systematic review here employed is fully available at http://www.crd.york.ac.
uk/PROSPERO, and it has been registered on the PROSPERO: International prospective register of
systematic reviews (accession number CRD42019120737).
4.4. Statistical Analysis
RevMan 5.3 software was used for statistical analysis. Based on the absence or presence of
heterogeneity, a random-effects model (the DerSimonian–Laird method) or a fixed-effects model (the
Mantel–Haenszel method) [29,30] was used to generate the summary estimates. The I2 statistic, with
percentage values of 25%, 50% and 75%, showing low, moderate and high heterogeneity, respectively,
and a Q-test, were used to assess statistical heterogeneity [31]. The fixed-effects model, or alternatively,
the random-effects model, was employed when p > 0.1 and I2 < 50% were achieved. For each study,
time-to-event variables, including HRs with 95% CI, OS, PFS and dichotomous variables, such as RRs
with 95% CIs, were calculated. Statistical significance was agreed at the value of p < 0.05. According to
PD-L1 status, age (65 years was the cut-off), tumour location (gastric vs. gastro-oesophageal junction),
sex and ECOG performance status (1 vs. 0), we scheduled a subgroup analysis for OS.
Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/2/448/s1.
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